Inhibitor of nuclear factor kappa-B kinase complex (IKK complex)

The Inhibitor of nuclear factor kappa-B kinase (IκB kinase or IKK) complex is a central signaling hub that regulates the NF-κB transcription factor family, which is essential for mediating inflammatory and immune responses (Source: NIH, PMC6162708). The complex is typically composed of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ (NEMO). Activation of the IKK complex leads to the phosphorylation of IκB proteins, triggering their ubiquitination and subsequent degradation by the 26S proteasome (Source: UniProt P51817). This process releases NF-κB dimers to enter the nucleus and activate the transcription of genes involved in cell proliferation, survival, and the production of pro-inflammatory cytokines. Aberrant activation of the IKK/NF-κB pathway is a hallmark of many chronic inflammatory diseases and malignancies, making it a high-priority target for therapeutic intervention (Source: NIH, PMID: 24037311). While many direct IKK inhibitors have been developed, clinical success has been limited by the pathway's broad physiological roles, leading to concerns regarding systemic toxicity and immunosuppression (Source: NIH, PMID: 30142927).

Other names

I-kappa-B kinase complexIKKNF-kappa-B pathway componentsIkappaB kinaseIKK alpha/beta/gamma complex

Drugs targeting this complex primarily act by inhibiting the catalytic activity of IKKβ or IKKα, or by preventing the phosphorylation and subsequent proteasomal degradation of inhibitory IκB proteins, thereby sequestering NF-κB in the cytoplasm and blocking its transcriptional activity (Source: NIH, PMID: 30142927).